Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (211-220 of 259) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III TrialFrançoise Rothé, Maria Joao Silva, David Venet, et al.
Journal of the National Cancer Institute|June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer PatientsMatteo Lambertini, Christine Campbell, José Bines, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerIan J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO studySerena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trialMarion Procter, Thomas M Suter, Evandro de Azambuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy UpdateSibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.
Journal of the National Cancer Institute|May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted TherapyMatteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
Plos One|August 31, 2013
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerOtto Metzger-Filho, Aurélie Catteau, Stefan Michiels, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Cancer Treatment Reviews|June 19, 2023
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysisCarlotta Becherini, Luca Visani, Saverio Caini, et al.
Pageof 26

Showing results (211-220 of 259) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III TrialFrançoise Rothé, Maria Joao Silva, David Venet, et al.
Journal of the National Cancer Institute|June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer PatientsMatteo Lambertini, Christine Campbell, José Bines, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerIan J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO studySerena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trialMarion Procter, Thomas M Suter, Evandro de Azambuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy UpdateSibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.
Journal of the National Cancer Institute|May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted TherapyMatteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
Plos One|August 31, 2013
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerOtto Metzger-Filho, Aurélie Catteau, Stefan Michiels, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Cancer Treatment Reviews|June 19, 2023
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysisCarlotta Becherini, Luca Visani, Saverio Caini, et al.
Pageof 26